Biofire
BCID2 Panel Significantly Reduces Time to Appropriate Therapy in Gram-Negative BSIs
Implementation of the BioFire FilmArray BCID2 (bioMérieux) resulted in clinically significant reduced time ...
AUGUST 6, 2025
Rapid Diagnostic Testing with BCID2 Panel Improves Time to Optimal Therapy
Many patients with bloodstream infections achieved optimal therapy within 48 hours using the Biofire Blood Culture ...
JUNE 2, 2025
DA Clears New Versions of bioMérieux Biofire Filmarray GI Panel Mid
The FDA granted marketing clearance to bioMérieux for its Biofire Filmarray GI Panel Mid, which tests for 11 ...
FEBRUARY 14, 2025
Negative Results on BioFire Pneumonia Panel Allow Antibiotic Discontinuation
A rapid multiplexed molecular panel facilitated safe discontinuation of antibiotic therapy in patients with ...
OCTOBER 25, 2024
FDA Clears bioMérieux Biofire Spotfire R/ST Panel and AST System Vitek Reveal
The FDA cleared two rapid diagnostic panels by bioMérieux—the Biofire Spotfire Respiratory/Sore Throat ...
JULY 1, 2024
Rapid Diagnostic Panel Cuts Time to Effective Therapy for Resistant BSIs
Implementing a rapid diagnostic panel reduced time to effective therapy for resistant bloodstream infections.
MAY 13, 2024
FDA Clears bioMérieux Biofire Spotfire Respiratory/Sore Throat Panel
The FDA cleared the BioFire Spotfire Respiratory/Sore Throat Panel. It also received a Clinical Laboratory ...
MARCH 27, 2024
For Ceftriaxone Resistance in Enterbacterales, bioMérieux’s BCID2 Panel Appears Superior to Other Predictive Tools
The BioFire FilmArray Blood Culture Identification 2 Panel outperformed two previously published scoring tools for ...
OCTOBER 15, 2023
BCID2 Rapid Diagnostic Panel Shortens Time to Effective Therapy
Use of the BioFire BCID2 rapid diagnostic test combined with a pharmacist-run ASP initiative improved time to ...
MAY 25, 2023
BioFire Sparks Fireworks With Data-Driven Software Solution
The in vitro diagnostics company bioMérieux launched BioFire Fireworks, an innovative and integrated ...
APRIL 5, 2023
FDA Clears New bioMérieux Respiratory Diagnostic System and Panel
The FDA issued a 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the ...
FEBRUARY 9, 2023
